SCHEDULE: CVI Investments and Heights Capital Management Report 8.5% Stake in Silexion Therapeutics

CVI Investments and Heights Capital Management jointly report beneficial ownership of 8.5% of Silexion Therapeutics' ordinary shares as of January 15, 2025.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G with the SEC, reporting their ownership stake in Silexion Therapeutics Corp.
• As of January 15, 2025, they collectively beneficially own 339,000 ordinary shares, representing 8.5% of the outstanding shares.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and may exercise voting and dispositive power over the shares.
• Both CVI Investments and Heights Capital Management disclaim beneficial ownership of the shares except for their pecuniary interest.
• The filing indicates that Silexion Therapeutics had 3,995,130 shares outstanding as of January 17, 2025, excluding shares underlying pre-funded warrants.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

Schedule 13G filings are standard practice for investment firms exceeding a 5% ownership stake in a publicly traded company, providing transparency to the market.

Stakeholder Impact

• Shareholders are informed about the significant ownership stake held by CVI Investments and Heights Capital Management.
• The filing provides transparency regarding the ownership structure of Silexion Therapeutics.

Key Dates

Keywords

Silexion Therapeutics, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Ordinary Shares, Investment Manager